Literature DB >> 17599452

Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years.

Carmelinda Ruggiero1, Antonio Cherubini, Edgar Miller, Marcello Maggio, Samer S Najjar, Fulvio Lauretani, Stefania Bandinelli, Umberto Senin, Luigi Ferrucci.   

Abstract

The role of uric acid (UA) in the process of atherothrombosis is controversial. Although serum UA has powerful antioxidant properties, epidemiological studies showed that UA was a risk factor for cardiovascular diseases and was positively associated with proinflammatory markers. Relations between baseline UA and changes in UA circulating levels with C-reactive protein (CRP) and interleukin-6 (IL-6) after 3 years of follow-up in a cohort of 892 Italian men and women aged 21 to 98 years was investigated. Subjects had complete baseline and follow-up data for UA, inflammatory markers, and covariates. An autoregressive approach was used to study such a relation. In adjusted analyses, baseline UA and changes in UA predicted a 3-year change in CRP (p = 0.028), but not IL-6 (p = 0.101). The relation between UA and CRP persisted after adjustment for baseline IL-6. Subjects with high UA at baseline had a progressively higher probability of developing clinically relevant increased IL-6 (>2.5 pg/ml) and CRP (>3 mg/L) during 3 years. In conclusion, our study suggests that in a population-based cohort, baseline UA and changes in circulating UA during 3 years of follow-up predict changes in circulating CRP independent of relevant confounders, including baseline IL-6.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599452      PMCID: PMC2674322          DOI: 10.1016/j.amjcard.2007.02.065

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

Authors:  Thomas A Pearson; George A Mensah; R Wayne Alexander; Jeffrey L Anderson; Richard O Cannon; Michael Criqui; Yazid Y Fadl; Stephen P Fortmann; Yuling Hong; Gary L Myers; Nader Rifai; Sidney C Smith; Kathryn Taubert; Russell P Tracy; Frank Vinicor
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

3.  Serum urate as an independent predictor of poor outcome and future vascular events after acute stroke.

Authors:  Christopher J Weir; Scott W Muir; Matthew R Walters; Kennedy R Lees
Journal:  Stroke       Date:  2003-07-03       Impact factor: 7.914

4.  Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging.

Authors:  Stefan D Anker; Wolfram Doehner; Mathias Rauchhaus; Rakesh Sharma; Darrel Francis; Christoph Knosalla; Constantinos H Davos; Mariantonietta Cicoira; Waqar Shamim; Michel Kemp; Robert Segal; Karl Josef Osterziel; Francisco Leyva; Roland Hetzer; Piotr Ponikowski; Andrew J S Coats
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

Review 5.  Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?

Authors:  Richard J Johnson; Duk-Hee Kang; Daniel Feig; Salah Kivlighn; John Kanellis; Susumu Watanabe; Katherine R Tuttle; Bernardo Rodriguez-Iturbe; Jaime Herrera-Acosta; Marilda Mazzali
Journal:  Hypertension       Date:  2003-04-21       Impact factor: 10.190

6.  Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors.

Authors:  Mayumi Saito; Toshihiko Ishimitsu; Junichi Minami; Hidehiko Ono; Masami Ohrui; Hiroaki Matsuoka
Journal:  Atherosclerosis       Date:  2003-03       Impact factor: 5.162

7.  Allopurinol improves endothelial dysfunction in chronic heart failure.

Authors:  Colin A J Farquharson; Robert Butler; Alexander Hill; Jill J F Belch; Allan D Struthers
Journal:  Circulation       Date:  2002-07-09       Impact factor: 29.690

8.  National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors:  Andrew S Levey; Josef Coresh; Ethan Balk; Annamaria T Kausz; Adeera Levin; Michael W Steffes; Ronald J Hogg; Ronald D Perrone; Joseph Lau; Garabed Eknoyan
Journal:  Ann Intern Med       Date:  2003-07-15       Impact factor: 25.391

9.  Hyperuricemia in childhood primary hypertension.

Authors:  Daniel I Feig; Richard J Johnson
Journal:  Hypertension       Date:  2003-08-04       Impact factor: 10.190

10.  Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers.

Authors:  N Nakanishi; M Okamoto; H Yoshida; Y Matsuo; K Suzuki; K Tatara
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

View more
  28 in total

1.  Serum uric acid and cardiovascular disease.

Authors:  Adriana Iliesiu; Alexandru Campeanu; Dinu Dusceac
Journal:  Maedica (Buchar)       Date:  2010-07

2.  Plateletcrit. A platelet marker associated with saphenous vein graft disease.

Authors:  I Akpinar; M R Sayin; Y C Gursoy; T Karabag; E Kucuk; M C Buyukuysal; M Aydin; I C Haznedaroglu
Journal:  Herz       Date:  2013-04-12       Impact factor: 1.443

3.  An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Isabella Laura Simone; Rosa Capozzo; Rosanna Tortelli; Antonio Leo; Eustachio D'Errico; Giancarlo Logroscino
Journal:  J Neurol       Date:  2010-09-15       Impact factor: 4.849

4.  Ischemic heart diseases in Egypt: role of xanthine oxidase system and ischemia-modified albumin.

Authors:  Ola Sayed Ali; Hanan Muhammad Abdelgawad; Makram Sayed Mohammed; Rehab Refaat El-Awady
Journal:  Heart Vessels       Date:  2013-10-04       Impact factor: 2.037

5.  The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome.

Authors:  Luciano F Drager; Heno F Lopes; Cristiane Maki-Nunes; Ivani C Trombetta; Edgar Toschi-Dias; Maria Janieire N N Alves; Raffael F Fraga; Jonathan C Jun; Carlos E Negrão; Eduardo M Krieger; Vsevolod Y Polotsky; Geraldo Lorenzi-Filho
Journal:  PLoS One       Date:  2010-08-11       Impact factor: 3.240

6.  Uric acid and dementia in community-dwelling older persons.

Authors:  Carmelinda Ruggiero; Antonio Cherubini; Fulvio Lauretani; Stefania Bandinelli; Marcello Maggio; Angelo Di Iorio; Giovanni Zuliani; Charalampos Dragonas; Umberto Senin; Luigi Ferrucci
Journal:  Dement Geriatr Cogn Disord       Date:  2009-04-01       Impact factor: 2.959

Review 7.  The association between metabolic syndrome components and the development of atherosclerosis.

Authors:  Anahita Aboonabi; Roselyn Rose' Meyer; Indu Singh
Journal:  J Hum Hypertens       Date:  2019-10-21       Impact factor: 3.012

8.  The value of serum uric Acid as a mortality prediction in critically ill children.

Authors:  Nakysa Hooman; Mitra Mehrazma; Shahrbanoo Nakhaii; Hasan Otukesh; Maziar Moradi-Lakeh; Neda Dianati-Maleki; Arash Ehteshami-Afshar
Journal:  Iran J Pediatr       Date:  2010-09       Impact factor: 0.364

9.  Serum uric acid predicts progression of subclinical coronary atherosclerosis in individuals without renal disease.

Authors:  Ticiana C Rodrigues; David M Maahs; Richard J Johnson; Diana I Jalal; Gregory L Kinney; Christopher Rivard; Marian Rewers; Janet K Snell-Bergeon
Journal:  Diabetes Care       Date:  2010-08-26       Impact factor: 17.152

10.  Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based Colaus study.

Authors:  Tanica Lyngdoh; Pedro Marques-Vidal; Fred Paccaud; Martin Preisig; Gérard Waeber; Murielle Bochud; Peter Vollenweider
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.